title: Hitting back HIT.
authors.forename: Dilip
authors.initials: D
authors.lastname: Gude
mesh_terms: D000906:Antibodies / Q000032:analysis; D000925:Anticoagulants / Q000009:adverse effects*; D000991:Antithrombins / Q000627:therapeutic use; D001120:Arginine / Q000031:analogs & derivatives; D001562:Benzimidazoles / Q000627:therapeutic use; D002809:Chondroitin Sulfates / Q000627:therapeutic use; D000069604:Dabigatran; D003871:Dermatan Sulfate / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D000077425:Fondaparinux; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology; D006497:Heparan Sulfate / Q000627:therapeutic use; D006629:Hirudins; D010446:Peptide Fragments / Q000627:therapeutic use; D010875:Pipecolic Acids / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011134:Polysaccharides / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D013449:Sulfonamides; D013917:Thrombin / Q000037:antagonists & inhibitors; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000628:therapy*
chemical_list: D000906:Antibodies; D000925:Anticoagulants; D000991:Antithrombins; D001120:Arginine; D001562:Benzimidazoles; D002809:Chondroitin Sulfates; D000069604:Dabigatran; D003871:Dermatan Sulfate; D005343:Fibrinolytic Agents; D000077425:Fondaparinux; D006493:Heparin; D006497:Heparan Sulfate; D006629:Hirudins; D010446:Peptide Fragments; D010875:Pipecolic Acids; D010975:Platelet Aggregation Inhibitors; D011134:Polysaccharides; D011725:Pyridines; D011994:Recombinant Proteins; D013449:Sulfonamides; D013917:Thrombin; C035838:danaparoid; C031942:argatroban; C074619:bivalirudin